BidaskClub cut shares of Assembly Biosciences (NASDAQ:ASMB) from a strong-buy rating to a buy rating in a research report report published on Friday morning.
A number of other research firms also recently weighed in on ASMB. Zacks Investment Research downgraded shares of Assembly Biosciences from a buy rating to a hold rating in a report on Wednesday, March 14th. Jefferies Group boosted their target price on shares of Assembly Biosciences to $75.00 and gave the stock a buy rating in a report on Thursday, March 8th. ValuEngine upgraded shares of Assembly Biosciences from a sell rating to a hold rating in a report on Saturday, February 3rd. Finally, B. Riley began coverage on shares of Assembly Biosciences in a report on Friday, January 5th. They issued a neutral rating and a $35.00 target price on the stock. Three equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company. The stock presently has a consensus rating of Buy and an average price target of $54.25.
Assembly Biosciences (NASDAQ:ASMB) traded down $2.95 during trading on Friday, hitting $55.22. 128,347 shares of the stock were exchanged, compared to its average volume of 169,846. Assembly Biosciences has a 12-month low of $18.60 and a 12-month high of $67.36. The company has a market cap of $1,178.02, a P/E ratio of -18.59 and a beta of 0.57.
Hedge funds have recently added to or reduced their stakes in the stock. Parametric Portfolio Associates LLC boosted its stake in shares of Assembly Biosciences by 13.6% during the 2nd quarter. Parametric Portfolio Associates LLC now owns 10,078 shares of the biopharmaceutical company’s stock worth $208,000 after purchasing an additional 1,203 shares during the period. The Manufacturers Life Insurance Company boosted its stake in shares of Assembly Biosciences by 15,448.6% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 11,195 shares of the biopharmaceutical company’s stock worth $232,000 after purchasing an additional 11,123 shares during the period. Teacher Retirement System of Texas purchased a new position in shares of Assembly Biosciences during the 4th quarter worth about $242,000. MetLife Investment Advisors LLC purchased a new position in shares of Assembly Biosciences during the 4th quarter worth about $326,000. Finally, Virtus Fund Advisers LLC purchased a new position in shares of Assembly Biosciences during the 4th quarter worth about $361,000. 76.81% of the stock is owned by hedge funds and other institutional investors.
TRADEMARK VIOLATION WARNING: This news story was first posted by Ticker Report and is the property of of Ticker Report. If you are viewing this news story on another site, it was copied illegally and reposted in violation of international copyright & trademark law. The correct version of this news story can be read at https://www.tickerreport.com/banking-finance/3296205/assembly-biosciences-asmb-downgraded-to-buy-at-bidaskclub.html.
About Assembly Biosciences
Assembly Biosciences, Inc is a biotechnology company. The Company is engaged in developing two platform programs, such as a class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection, and a class of oral synthetic live therapeutics, which are designed to restore health to a dysbiotic microbiome.
Receive News & Ratings for Assembly Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Assembly Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.